摘要
目的探讨长期应用重组人血管内皮抑素（恩度）联合化疗治疗骨血管内皮细胞瘤肺转移的可行性。方法 1例骨血管内皮细胞瘤肺转移患者接受恩度与化疗联合治疗,恩度15mg静脉滴注1/日,化疗先后采用TE方案6周期（紫杉醇90mg d1、d8、d15,表阿霉素90mg d1,q4w）和TP方案4周期（紫杉醇90mg d1、d8,顺铂20mg d1-d5,q3w）,化疗结束后疗效评价PR,继续恩度单药长期治疗（恩度15mg d1-d14,q8w）。按照REC IST标准1.0版进行疗效评价。结果该例患者应用恩度联合紫杉类为主的治疗后获得PR,继续予恩度单药长期治疗,现已3年,取得了较长时间的疾病缓解和良好的生存质量。在长期应用恩度过程中未见药物相关不良反应,患者耐受性良好。结论持续应用恩度联合化疗取得最佳生物疗效后单药恩度长期治疗,这一治疗策略值得临床上进一步试用观察,以积累更多的经验。
Objective To explore the feasibility for long-term administration of rh-endostatin injection（endostar）combined with chemotherapy in the treatment of hemangioendothelioma of bone accompanying pulmonary metastasis.Methods One case of hemangioendothelioma of bone accompanying pulmonary metastasis was received endostar with dose of 15mg daily.Except for endostar,the patient was also treated with TE regimen（paclitaxel 90mg d1,d8,d15;epirubicin 90mg d1,q4w）for 6 cycles and TP regimen（paclitaxel 90mg d1,d8;cisplatin 20mg d1-d5,q3w）for 4 cycles.After all the chemotherapy with partial response,the endostar was used as maintenance therapy（endostar d1-d14 q8w）.Efficacy evaluation was conducted according to RECIST criteria.Results The patient got partial response for 3 years after the application of endostar maintenance therapy and endostar combined with taxane-based chemotherapy.During the period of using endostar as monotherapy,the patient got long-term disease control and good quality of life.There was no drug related adverse event during the therapy of endostar,and the patient was well tolerated.Conclusion Continued using of endostar combined with chemotherapy could achieve an convinced therapeutic effect.Then using endostar as maintenance treatment after patient got the optimal efficacy was feasible and profitable.This treatment strategy of long-term administration of endostar was worthy of further observation.
出处
《临床肿瘤学杂志》
CAS
2010年第9期838-841,共4页
Chinese Clinical Oncology
基金
南京军区"十一.五"医学科研面上项目
